Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.
Daihan Pharmaceutical Co.Ltd (023910) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.032x
Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has a cash flow conversion efficiency ratio of 0.032x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩9.47 Billion) by net assets (₩293.27 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Daihan Pharmaceutical Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Daihan Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Daihan Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FFD Financial Corp
PINK:FFDF
|
N/A |
|
Greenheart Gold Inc.
V:GHRT
|
-0.089x |
|
Mogotes Metals Inc.
V:MOG
|
-0.370x |
|
San Far Property Ltd
TW:9946
|
-0.043x |
|
TOLUF
OTCQX:TOLUF
|
N/A |
|
Nexen Corporation
KO:005720
|
0.031x |
|
NanoenTekInc
KQ:039860
|
0.031x |
|
Dusit Thani Public Company Limited
BK:DUSIT
|
0.122x |
Annual Cash Flow Conversion Efficiency for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Daihan Pharmaceutical Co.Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩275.99 Billion | ₩35.64 Billion | 0.129x | -17.59% |
| 2023-12-31 | ₩247.97 Billion | ₩38.86 Billion | 0.157x | +21.80% |
| 2022-12-31 | ₩225.40 Billion | ₩29.00 Billion | 0.129x | -35.76% |
| 2021-12-31 | ₩202.81 Billion | ₩40.62 Billion | 0.200x | +8.35% |
| 2020-12-31 | ₩181.92 Billion | ₩33.63 Billion | 0.185x | -12.58% |
| 2019-12-31 | ₩166.78 Billion | ₩35.26 Billion | 0.211x | -33.96% |
| 2018-12-31 | ₩140.36 Billion | ₩44.94 Billion | 0.320x | +81.40% |
| 2017-12-31 | ₩115.88 Billion | ₩20.45 Billion | 0.177x | -41.25% |
| 2016-12-31 | ₩92.94 Billion | ₩27.92 Billion | 0.300x | +28.43% |
| 2015-12-31 | ₩76.84 Billion | ₩17.98 Billion | 0.234x | +58.11% |
| 2014-12-31 | ₩64.10 Billion | ₩9.48 Billion | 0.148x | -- |